Recent Updates
Recently added Catalysts

Homeopathic drug C12

Phase 1

Healthy Subjects | Small molecule | Other |Pulmonx Corporation|Last Updated: Jul 10, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment29

FDA Designations

No designations recorded

Clinical trial landscape

Homeopathic drug C12 · 1 trial · 1 indication

Phase 1 1
NCT01061229Homeopathic Drug Proving TrialHealthy Subjects
COMPLETED29 Analytics
PHASE1COMPLETED
Homeopathic Drug Proving Trial
Healthy SubjectsUnlock trial analytics

Study Endpoints

Primary Endpoints

The primary outcome parameter is the number of characteristic proving symptoms per subject, derived from the qualitative data analysis of the homeopathic proving drug compared to placebo.
3 weeks

Secondary Endpoints

Total number of proving symptoms
3 weeks
Number of serious adverse events
3 weeks
Qualitative differences in the profiles of characteristic proving symptoms
3 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL

Treatment Arms

ArmTypeDescription
Homeopathic drug, potency C12EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
Homeopathic drug C12DRUGSubjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
PlaceboOTHERPlacebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Medical doctors or medical students * Not being treated for any acute or chronic diseases on the day of inclusion * Written informed consent. Exclusion Criteria: * Pregnant women or nursing mothers * Homeopathic treatment over the previous six weeks * Participation in anothe...

Countries:Germany
Unlock Eligibility Criteria